Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ocular Therapeut (OCUL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,085
  • Shares Outstanding, K 41,282
  • Annual Sales, $ 1,920 K
  • Annual Income, $ -63,390 K
  • 36-Month Beta 1.84
  • Price/Sales 65.30
  • Price/Cash Flow N/A
  • Price/Book 3.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.37
  • Low Estimate -0.38
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +15.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.46 +5.78%
on 02/08/19
4.10 -10.73%
on 01/16/19
-0.33 (-8.27%)
since 01/15/19
3-Month
3.46 +5.78%
on 02/08/19
6.88 -46.80%
on 11/30/18
-1.68 (-31.46%)
since 11/15/18
52-Week
3.46 +5.78%
on 02/08/19
8.28 -55.80%
on 06/14/18
-1.29 (-26.06%)
since 02/15/18

Most Recent Stories

More News
Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Inovalon Holdings, Inc....

SENS : 2.40 (+3.00%)
MMSI : 59.60 (+1.69%)
HIG : 48.73 (+1.02%)
SNPS : 101.65 (+1.03%)
INOV : 15.00 (+5.49%)
OCUL : 3.66 (-0.27%)
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza

Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.

CPIX : 5.54 (-5.14%)
HKMPF : 22.5000 (+10.57%)
BSTC : 71.62 (+5.35%)
OCUL : 3.66 (-0.27%)
Ocular Therapeutix(TM) Announces Completion of Debt Refinancing

--Cash Runway Extended into Third Quarter of 2019

OCUL : 3.66 (-0.27%)
Ocular Therapeutix(TM) Added to Nasdaq Biotechnology Index

SOURCE: Ocular Therapeutix(TM), Inc.">

OCUL : 3.66 (-0.27%)
Corelogic Inc Has Returned 24.8% Since SmarTrend Recommendation (CLGX)

SmarTrend identified a Downtrend for Corelogic Inc (NYSE:CLGX) on July 26th, 2018 at $51.30. In approximately 4 months, Corelogic Inc has returned 24.83% as of today's recent price of $38.56.

CTT : 9.43 (+0.86%)
EPAY : 47.96 (+1.98%)
EXAS : 88.55 (+0.49%)
WYNN : 124.51 (+0.87%)
HMSY : 32.21 (+3.01%)
GLT : 13.95 (+2.72%)
MHK : 139.21 (+0.30%)
BBW : 5.03 (+1.00%)
CDW : 94.84 (+1.05%)
COUP : 96.33 (+1.17%)
QTWO : 66.79 (-0.09%)
DENN : 17.74 (+0.91%)
MYL : 31.84 (+1.02%)
DFRG : 8.37 (-1.53%)
GCAP : 7.04 (+3.23%)
FEYE : 17.23 (-1.82%)
MXIM : 55.85 (+0.11%)
POL : 32.80 (+2.53%)
AN : 39.08 (+2.09%)
TWO : 13.89 (+0.43%)
HUBG : 45.73 (+0.75%)
AR : 9.61 (+5.95%)
RE : 216.93 (+1.35%)
NNBR : 10.35 (+0.58%)
ARE : 134.86 (+0.72%)
CVI : 42.58 (+1.16%)
CERS : 6.47 (+3.52%)
NDAQ : 87.76 (+0.69%)
ELLI : 98.90 (+0.15%)
BLDR : 13.62 (+0.74%)
EGRX : 41.90 (+3.38%)
RGLD : 87.19 (-0.32%)
PRGO : 48.95 (+0.72%)
PENN : 24.41 (-0.29%)
NTAP : 64.03 (+0.58%)
IBM : 138.03 (+1.14%)
NTRI : 43.33 (+0.32%)
BANR : 60.82 (+3.35%)
CWT : 50.93 (+0.16%)
STAA : 36.42 (+3.55%)
ATHN : 134.99 (+0.01%)
CL : 66.48 (+1.57%)
TFSL : 16.93 (+1.26%)
UFPI : 32.23 (+1.00%)
SDRL : 8.66 (+4.34%)
GOV : 6.87 (-5.50%)
HQY : 77.10 (+1.74%)
IPGP : 154.88 (+3.56%)
MINI : 36.07 (+0.08%)
CMTL : 27.20 (+0.93%)
CHD : 64.69 (+0.53%)
GPI : 61.77 (+3.90%)
HRL : 43.20 (+0.35%)
RARE : 56.65 (+2.15%)
MLI : 32.39 (+1.25%)
GPS : 25.07 (+0.60%)
CHS : 5.68 (+3.09%)
RYAM : 14.09 (+2.47%)
PBI : 7.05 (+0.86%)
NUVA : 58.59 (+0.15%)
IMDZ : 1.44 (-1.37%)
CAMP : 14.57 (+2.61%)
NOC : 286.98 (+2.27%)
AEL : 32.77 (+5.00%)
EBIX : 58.57 (+0.97%)
DISCA : 29.30 (+1.84%)
GPOR : 8.04 (+4.28%)
BGS : 26.21 (+0.77%)
TECH : 191.63 (+1.63%)
PCH : 35.47 (+1.31%)
NOV : 29.81 (+2.69%)
TECD : 104.15 (+0.97%)
DISCK : 27.65 (+1.69%)
DECK : 146.29 (+2.54%)
NOW : 234.89 (+0.37%)
MGLN : 64.82 (+2.08%)
IEX : 144.12 (+2.15%)
PTC : 91.93 (+1.03%)
AVT : 44.12 (+0.23%)
RGS : 18.36 (-0.16%)
BSFT : 54.95 (+0.09%)
FOSL : 14.88 (-2.43%)
WAL : 46.00 (+2.13%)
IVR : 15.97 (+0.19%)
ENR : 45.63 (+0.20%)
ISBC : 12.65 (+1.12%)
SHOO : 34.41 (+0.17%)
HDP : 14.68 (+1.80%)
AWK : 98.05 (+0.82%)
OMED : 0.89 (+15.58%)
LADR : 17.56 (+0.11%)
BIG : 32.27 (+0.34%)
WY : 25.54 (+0.47%)
JBLU : 17.96 (-0.66%)
GNMK : 6.31 (+3.95%)
FORM : 15.93 (+0.50%)
PFSI : 22.86 (+1.51%)
NEWM : 13.63 (+1.56%)
KFRC : 38.13 (+2.94%)
HOLX : 46.29 (+2.34%)
TMK : 83.36 (+1.87%)
AXTA : 26.68 (+0.79%)
PGEM : 21.65 (unch)
CLH : 60.04 (+1.13%)
CLI : 21.08 (+0.33%)
NRG : 42.46 (-0.35%)
CLGX : 39.74 (+0.97%)
SFLY : 46.07 (+0.37%)
ICUI : 253.28 (+1.38%)
CARA : 17.05 (+3.02%)
WTR : 35.62 (-0.08%)
NTGR : 35.60 (+0.74%)
OLED : 118.49 (+0.95%)
VNDA : 21.11 (+4.92%)
HIBB : 17.62 (-0.23%)
FFBC : 27.98 (+2.79%)
DLTR : 98.85 (+0.32%)
EQT : 18.93 (+4.01%)
OMER : 14.04 (-2.16%)
KTOS : 16.95 (unch)
SRCL : 45.56 (+1.18%)
GES : 20.45 (+0.15%)
KMX : 62.06 (+1.47%)
PLAB : 11.43 (+0.09%)
NCS : 7.67 (-1.29%)
MAR : 121.05 (+2.05%)
MRVL : 18.83 (-1.88%)
UAL : 88.31 (+0.18%)
CNK : 37.31 (+0.32%)
NATH : 74.29 (+3.61%)
TPH : 13.09 (+0.08%)
OCUL : 3.66 (-0.27%)
SKYW : 55.68 (-0.84%)
HIVE : 4.43 (+1.84%)
GAIA : 11.61 (+2.47%)
ESRX : 92.33 (-3.62%)
PHM : 27.12 (+0.78%)
EBS : 66.16 (+1.77%)
CACI : 180.06 (+1.04%)
SAVE : 61.67 (+0.41%)
EZPW : 10.02 (+1.01%)
TPX : 56.99 (+1.62%)
KLAC : 108.19 (+0.98%)
ULTA : 306.36 (+0.45%)
WWE : 87.46 (-1.59%)
ESV : 4.78 (+6.46%)
LTRPA : 16.68 (-1.18%)
DAL : 51.08 (+1.19%)
BMY : 51.67 (+1.65%)
ECL : 163.48 (+1.16%)
CHRW : 91.45 (+0.83%)
WWW : 39.58 (+2.59%)
ETH : 19.76 (+1.28%)
IART : 51.06 (+0.81%)
LE : 17.51 (+1.92%)
LH : 150.17 (+2.32%)
HZO : 19.61 (+5.49%)
MTD : 668.86 (+0.90%)
OSTK : 19.73 (+2.92%)
LDOS : 63.37 (+1.67%)
SAGE : 160.93 (+1.80%)
CIEN : 40.21 (+1.26%)
MTW : 17.47 (+3.19%)
AMC : 13.79 (+1.03%)
NDLS : 7.51 (-0.66%)
EFII : 27.59 (+0.91%)
SIVB : 246.95 (+2.73%)
MU : 41.99 (-0.57%)
DSW : 27.47 (+0.29%)
VRNT : 52.39 (+0.42%)
OII : 16.65 (+3.29%)
SAFM : 121.10 (+0.53%)
DATA : 129.34 (-0.52%)
TLYS : 11.86 (+0.42%)
TREE : 316.65 (+2.49%)
TRUP : 29.26 (+5.98%)
AMCX : 64.46 (+2.25%)
EXPD : 73.64 (-0.43%)
SUPN : 39.10 (+2.25%)
NBIX : 84.32 (-0.27%)
SAIC : 76.59 (+2.71%)
CBM : 37.68 (+5.25%)
BURL : 162.81 (+0.33%)
AMED : 136.22 (-1.81%)
EXPR : 5.29 (+1.73%)
SBH : 18.71 (+0.11%)
ATSG : 24.90 (+3.02%)
PLT : 49.62 (+3.53%)
QDEL : 65.43 (+1.76%)
NLNK : 1.53 (+3.38%)
STMP : 201.24 (+1.90%)
IPCC : 142.80 (+0.32%)
BMTC : 39.73 (+2.58%)
STML : 11.49 (+3.42%)
EGL : 29.10 (+0.24%)
LUV : 57.70 (-0.52%)
CCL : 57.25 (+0.26%)
INOV : 15.00 (+5.49%)
COTY : 11.04 (-0.36%)
MGM : 28.21 (+3.07%)
AKBA : 6.65 (+2.78%)
LGIH : 60.37 (+0.62%)
CDNS : 52.58 (+1.78%)
CRZO : 12.68 (+4.11%)
TEN : 36.25 (+6.03%)
HAIN : 17.76 (+1.78%)
Ocular Therapeutix(TM) Announces the Hiring of Chad Brines, Vice President, Sales

Ocular Therapeutix(TM), Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions...

OCUL : 3.66 (-0.27%)
Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock

Ocular Therapeutix (OCUL) needs investors to pay close attention to the stock based on moves in the options market lately.

OCUL : 3.66 (-0.27%)
Global Glaucoma Treatment Market Forecast to 2023 Featuring Teva Pharmaceuticals, Ocular Therapeutix, Pfizer, Bausch Health, Novartis, Allergan, Aerie Pharmaceuticals & Akorn

The "Global Glaucoma Treatment Market: Analysis By Indication, By Drug Class, By Sales Channel, By Region, By Country (2018 Edition): Forecast to 2023" report has been added to ResearchAndMarkets.com's...

AERI : 41.75 (+1.66%)
AGN : 139.07 (+0.29%)
OCUL : 3.66 (-0.27%)
Shares of Ocular Therapeut Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (OCUL , LCI , SUPN , MDCO , BMY )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

LCI : 9.82 (+5.03%)
SUPN : 39.10 (+2.25%)
OCUL : 3.66 (-0.27%)
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Ocular Therapeut (OCUL , ENDP , AERI , NKTR , ZGNX )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

AERI : 41.75 (+1.66%)
ENDP : 10.57 (+0.48%)
OCUL : 3.66 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade OCUL with:

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

2nd Resistance Point 3.75
1st Resistance Point 3.70
Last Price 3.66
1st Support Level 3.63
2nd Support Level 3.61

See More

52-Week High 8.28
Fibonacci 61.8% 6.44
Fibonacci 50% 5.87
Fibonacci 38.2% 5.30
Last Price 3.66
52-Week Low 3.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar